Catalog No.
DHD17406
Expression system
Mammalian Cells
Species reactivity
Human
Host species
Mouse Hybrid Rat
Isotype
IgG2a-kappa/IgG2b-lambda
Clonality
Monoclonal
Target
Epithelial glycoprotein 314, hEGP314, Major gastrointestinal tumor-associated protein GA733-2, EGP314, TACSTD1, Adenocarcinoma-associated antigen, TROP1, EPCAM, Epithelial glycoprotein, KS 1/4 antigen, Tumor-associated calcium signal transducer 1, M4S1, CD326, Ep-CAM, EGP, Epithelial cell adhesion molecule, M1S2, KSA, Cell surface glycoprotein Trop-1, GA733-2, Epithelial cell surface antigen, MIC18, T3E, T-cell surface antigen T3/Leu-4 epsilon chain, CD3e, CD3E, T-cell surface glycoprotein CD3 epsilon chain
Concentration
1 mg/ml
Endotoxin level
Please contact with the lab for this information.
Purity
>95% as determined by SDS-PAGE.
Purification
Protein A/G purified from cell culture supernatant.
Accession
P16422 & P07766
Applications
Research Grade Biosimilar
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Alternative Names
Bispecific, Musmus G2a kappa, anti-EPCAM (Ho-3/TP-A-01) / Rat sp. G2b lambda, anti-CD3E (26/II/6-1.2), TPBs01, CAS: 509077-98-9
Clone ID
Catumaxomab
Catumaxomab: in malignant ascites, PMID: 22676343
Catumaxomab: clinical development and future directions, PMID: 20190561
Catumaxomab--trifunctional anti-EpCAM antibody used to treat malignant ascites, PMID: 20624115
Bispecific antibodies for cancer therapy: A review, PMID: 29269044
Catumaxomab: a bispecific trifunctional antibody, PMID: 19927225
The contribution of catumaxomab in the treatment of malignant ascites in patients with ovarian cancer: a review of the literature, PMID: 23644922
Bispecific antibodies: design, therapy, perspectives, PMID: 29403265
Palliation of malignant ascites, PMID: 30903617
The evolving role of catumaxomab in gastric cancer, PMID: 18694358
Development and approval of the trifunctional antibody catumaxomab (anti-EpCAM x anti-CD3) as a targeted cancer immunotherapy, PMID: 20347527
Catumaxomab with Activated T-cells Efficiently Lyses Chemoresistant EpCAM-positive Triple-negative Breast Cancer Cell Lines, PMID: 29970561
Catumaxomab with and without prednisolone premedication for the treatment of malignant ascites due to epithelial cancer: results of the randomised phase IIIb CASIMAS study, PMID: 24965536
The trifunctional antibody catumaxomab in treatment of malignant ascites and peritoneal carcinomatosis, PMID: 20919824
Re-challenge with catumaxomab in patients with malignant ascites: results from the SECIMAS study, PMID: 25367854
Bispecific antibodies targeting dual tumor-associated antigens in cancer therapy, PMID: 32989604
Antibody Based EpCAM Targeted Therapy of Cancer, Review and Update, PMID: 29295696
Review of catumaxomab in the treatment of malignant ascites, PMID: 21188120
Efficacy of catumaxomab in tumor spheroid killing is mediated by its trifunctional mode of action, PMID: 20652245
Randomised phase II trial to investigate catumaxomab (anti-EpCAM × anti-CD3) for treatment of peritoneal carcinomatosis in patients with gastric cancer, PMID: 29988111
Immunotherapy of peritoneal carcinomatosis with catumaxomab, PMID: 21358211
The trifunctional antibody catumaxomab amplifies and shapes tumor-specific immunity when applied to gastric cancer patients in the adjuvant setting, PMID: 23955093
Management of drainage for malignant ascites in gynaecological cancer, PMID: 31825525
Extraperitoneal response to intraperitoneal immunotherapy with catumaxomab in a patient with cutaneous lymphangiosis carcinomatosa from ovarian cancer: a case report and review of the literature, PMID: 22744709
Immunological changes in the ascites of cancer patients after intraperitoneal administration of the bispecific antibody catumaxomab (anti-EpCAM×anti-CD3), PMID: 26049121
Novel monoclonal antibodies for cancer treatment: the trifunctional antibody catumaxomab (removab), PMID: 21716847
The role of relative lymphocyte count as a biomarker for the effect of catumaxomab on survival in malignant ascites patients: results from a phase II/III study, PMID: 24714773
Catumaxomab for the treatment of malignant ascites in patients with chemotherapy-refractory ovarian cancer: a phase II study, PMID: 25254563
Detection of soluble EpCAM (sEpCAM) in malignant ascites predicts poor overall survival in patients treated with catumaxomab, PMID: 26296970
A phase II study of catumaxomab administered intra- and postoperatively as part of a multimodal approach in primarily resectable gastric cancer, PMID: 25214034
Humoral response to catumaxomab correlates with clinical outcome: results of the pivotal phase II/III study in patients with malignant ascites, PMID: 21702044
The trifunctional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer: Results of a prospective randomized phase II/III trial, PMID: 20473913
Pharmacokinetics, immunogenicity and bioactivity of the therapeutic antibody catumaxomab intraperitoneally administered to cancer patients, PMID: 20565453
Alternative molecular formats and therapeutic applications for bispecific antibodies, PMID: 25637431
Intra- and postoperative catumaxomab in patients with epithelial ovarian cancer: safety and two-year efficacy results from a multicentre, single-arm, phase II study, PMID: 25225907
Catumaxomab: malignant ascites: unjustified marketing authorisation, PMID: 21180374
Molecule of the month: catumaxomab, PMID: 19609465
A phase I trial of intravenous catumaxomab: a bispecific monoclonal antibody targeting EpCAM and the T cell coreceptor CD3, PMID: 25814216
Structural and functional characterization of the trifunctional antibody catumaxomab, PMID: 20418662
Systemic effect of catumaxomab in a patient with metastasized colorectal cancer: a case report, PMID: 24380380
Immune-mediated liver injury of the cancer therapeutic antibody catumaxomab targeting EpCAM, CD3 and Fcγ receptors, PMID: 27058902
Transient lymphocyte decrease due to adhesion and migration following catumaxomab (anti-EpCAM x anti-CD3) treatment in vivo, PMID: 22551544
Regression of liver metastases after treatment with intraperitoneal catumaxomab for malignant ascites due to breast cancer, PMID: 23197249
Catumaxomab, a rat/murine hybrid trifunctional bispecific monoclonal antibody for the treatment of cancer, PMID: 18535935
Immunomonitoring results of a phase II/III study of malignant ascites patients treated with the trifunctional antibody catumaxomab (anti-EpCAM x anti-CD3), PMID: 22044753
Influence of catumaxomab on tumor cells in bone marrow and blood in ovarian cancer, PMID: 19443405
Intraperitoneal catumaxomab therapy in a cirrhotic patient with malignant ascites due to urethelial carcinoma: a case report, PMID: 23038231
First surgical experience of intraperitoneal treatment with the trifunctional antibody catumaxomab (anti-EpCam x anti-CD3) for epithelial ovarian cancer, PMID: 21778311
Treatment of non-small cell lung cancer patients with the trifunctional monoclonal antibody catumaxomab (anti-EpCAM x anti-CD3): a phase I study, PMID: 17410361
Treatment of malignant pleural effusion with the trifunctional antibody catumaxomab (Removab) (anti-EpCAM x Anti-CD3): results of a phase 1/2 study, PMID: 19238019
Immunotherapy of peritoneal carcinomatosis with the antibody catumaxomab in colon, gastric, or pancreatic cancer: an open-label, multicenter, phase I/II trial, PMID: 21358214
For research use only. Not for human or drug use.
